ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
Open access · hybridAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 58 citations in OpenAlex.
- Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial.The oncologist · 2025Trial
- Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study.Signal transduction and targeted therapy · 2025Trial
- Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer.International journal of clinical oncology · 2026Article
- Third-line treatment of biliary tract cancers in a real-life setting.ESMO gastrointestinal oncology · 2026Article
- Deciphering the Molecular Landscape of Squamous Cell Carcinoma of the Anal Canal: From Biology to Precision Oncology.Cancers · 2026Review
- SEOM‑GETTHI clinical guideline for the practical management of molecular platforms (update 2026).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Clinical benefit of various HER2-directed regimens in gastrointestinal malignancies: a retrospective cohort study.BMC cancer · 2026Article
- Disparities in Gallbladder Cancer: Epidemiology, Molecular Mechanisms, and Clinical Implications.Molecular biology reports · 2026Review
- Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.Future oncology (London, England) · 2026Review
- Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151.Journal of gastrointestinal oncology · 2026Article
- Tumor-Agnostic Landscape withCurrent oncology (Toronto, Ont.) · 2026Observational
- Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas.International journal of molecular sciences · 2026Review
- HER2 and urothelial carcinoma: current understanding and future directions.Nature reviews. Urology · 2026Review
- Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Review
- Actionable mutations in pancreatic cancer: where targeted therapies are making a difference.BMJ open gastroenterology · 2025Review
- HER2-targeted therapy in colorectal cancer: a comprehensive review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- HER2-Positive Urothelial Carcinoma: Current Evidence on Targeted Agents and Immunotherapy-Based Combinations.Targeted oncology · 2025Review
- ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 3 countries.
Christopher J SweeneySouth Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-0398-6018
John D HainsworthSarah Cannon Research Institute, Nashville, TN.
Ron BoseWashington University School of Medicine, St Louis, MO.ORCID 0000-0003-1977-8894
Howard A BurrisSarah Cannon Research Institute, Nashville, TN.
Razelle KurzrockMedical College of Wisconsin Cancer Center, Milwaukee, WI.ORCID 0000-0003-4110-1214
Charles SwantonFrancis Crick Institute, London, United Kingdom.
Claire F FriedmanMemorial Sloan Kettering Cancer Center, New York, NY.
David R SpigelSarah Cannon Research Institute, Nashville, TN.ORCID 0000-0003-3215-9465
Tania SzadoGenentech, Inc, South San Francisco, CA.
Katja SchulzeGenentech, Inc, South San Francisco, CA.ORCID 0000-0003-3704-5651
Richard PriceGenentech, Inc, South San Francisco, CA.
Julia MalatoGenentech, Inc, South San Francisco, CA.
Amy A LoGenentech, Inc, South San Francisco, CA.ORCID 0000-0002-8614-6734
Jonathan LevyGenentech, Inc, South San Francisco, CA.ORCID 0000-0001-8055-8888
Yong WangGenentech, Inc, South San Francisco, CA.
Wei YuGenentech, Inc, South San Francisco, CA.
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6816-6072
Sarah Cannon · USCentre for Cancer Biology · AUMedical College of Wisconsin · USMemorial Sloan Kettering Cancer Center · USThe Francis Crick Institute · GBThe University of Texas MD Anderson Cancer Center · USWashington University in St. Louis · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MConvalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3MNCATS NIH HHS UL1 TR003167NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Monoclonal, HumanizedNeoplasmsProto-Oncogene Proteins p21(ras)AdultAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesHumansTrastuzumabAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespertuzumabProto-Oncogene Proteins p21(ras)Trastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.